Abbott Laboratories's (NYSE:ABT) share price is 31.0% higher in the past 12 months and has outperformed the overall US TECH market which is 3.9% higher in the same timeframe. This means a 27.1% greater return over the period which puts the share price as an outperformer vs other US TECH companies.
From 20 analysts that cover Abbott Laboratories's stock, the average rating is 4.0. This is a weighted average of 7 strong buys, 6 buys, 7 holds. This is 0.1 lower than a month ago which gives this factor a tea-score of 2/5.
• Abbott Labs Falls 3% (Investing.com)
Abbott Laboratories insider's have net been buying stock over the past 12 months, in the previous month insiders have been net buying. In fact the buy to sell ratio in the past month has been 50.0% which is 49.0% higher than the last 12 months buy to sell ratio. This put's Abbott Laboratories's Insiders in the top quintile vs their peers giving this factor a tea-score of 1/5.
For Abbott Laboratories, currently 76.5% of stock (1 billion shares) is owned by Institutions, 22.8% (802 million shares) is owned by Individuals, and 0.7% (2 million shares) is owned by company insiders. The CEO has a holding of 0.02% which is equivalent to 40 thousand shares with a market value of $129 million. This factor has a tea-score of 4/5.
As of 31 July 2019, the short interest for Abbott Laboratories has been 0.97% of the shares outstanding which is 171 billion shares. This is more than 1 month ago which had 0.81% of the shares outstanding which is 142 billion short interest in shares. This equals a tea-score of 5/5.
Abbott Laboratories's revenue in the last 12 months ending 30 June 2019 is $30Bn. Abbott Laboratories's average revenue growth for the last 4 years has been 5.1% which is currently lower than their comps of 6.2%.
Abbott Laboratories's free cash flow yield is 3.9% and has grown from 4 years ago. The free cash flow yield for Abbott Laboratories 1 year ago was 4.5% and 3 years ago it was 2.5%.
Abbott Laboratories pays dividends every 3 months and has done so since 02 April 2013. Dividends have been steadily increasing over the past 4 years from $0.24 (dividend yield of 0.52%) to $0.32 today (yield of 0.38%).
Abbott Laboratories's PE ratio is 52.1x. This is calculated from their EPS of $2.02 and price per share of $84.78. Abbott Laboratories's PE ratio values the company cheaper than 60% of it's competitors giving this factor a tea-score of 3/5.
Abbott Laboratories's PEG ratio is 1.4x. This is calculated from their PE ratio of 52.1x and their last 12 months growth rate of 0.372%. This is more attractive than their competitors so the tea-score for this factor is 3/5.
The PB ratio for Abbott Laboratories is 4.7x. This is cheaper than their competitors who have an average PB ratio of 8.7x. The tea-score is 2/5.
Abbott Laboratories's free cash flow yield is 3.9% which is ranked 1.0/5 when compared to its competitors. This is calculated from a free cash flow of - (as reported for the 12 months ending 30 June 2019) divided by its current market capitalisation of $149Bn. The average free cash flow yield across Abbott Laboratories's comps is 8.1%.
Abbott Laboratories's return on investment is 9.2%. This is more profitable than its competitors.
Abbott Laboratories's current ratio is calculated by (current assets) / (current liabilities) which equals 1.7x. This less attractive than their competitors and also worse than recommended for a healthy company.
Abbott Laboratories's debt to shareholder equity is 62.9%. This is worse than their competitors and also worse than advised for a well-managed balance sheet.
Abbott Laboratories's dividend payout ratio calculated against their free cash flow is low at 56.6%. This is in quintile 3 when measured against their comps.
Abbott Laboratories's has a good overall ESG rating of 63/100. Their competitors have a score between 41 and 81 with the average at 59.
What is the 52 week high for Abbott Laboratories stock quote?
Abbott Laboratories (NYSE:ABT) hit a new 52-week high on 23 July 2019 at a price of $88.74 with 4,049,100 shares traded that day. This is 4.7% higher than than its current price of $84.78 and 38.8% higher than the 52-week low of $63.93 on 21 August 2018. Average daily volume traded has been 5 million shares over the past 3 months.
What is the highest price Abbott Laboratories stock has ever been?
The all-time highs for Abbott Laboratories stock were reached on 23 July 2019, 27 days ago at a price of $88.74. This equates to a market capitalisation of $156Bn. The highest price reached is 4.7% higher than the current price of $84.78 with a current market cap of $149Bn.
What is the beta of Abbott Laboratories stock?
Abbott Laboratories stock moves 0.8x the US TECH market average which makes its beta higher than the overall market.
What is the volatility of Abbott Laboratories (ABT) stock?
Abbott Laboratories's stock has an annual volatility of 22.8% which is more volatile than the average US TECH market volatility of 16.3% which has made it a less safe stock to own in the past vs just owning the index for investors aiming for lower portfolio volatility.
What have Abbott Laboratories's share buybacks been over the past year?
Abbott Laboratories is currently running a share-buyback program and in the past year alone the company has repurchased 104 million of shares outstanding at a total expense of $23Trn. In the same time frame the share price has moved 31.0% higher which is an outperformance of 27.1% vs the overall market. Abbott Laboratories still has $420Trn of cash remaining on their balance sheet.
Who owns the most Abbott Laboratories stock?
Barry White is the largest individual shareholder in Abbott Laboratories with 1 billion shares. He is an independent director of Abbott Laboratories. The largest institutional holder is T-Rowe and they own 5.7% of the issue size with 100 million shares. T-Rowe have been net buying shares over the last 12 months as they own 1 million more shares than a year ago.
When did Abbott Laboratories beat earnings expectations in the last 4 years?
In the past 4 quarters Abbott Laboratories has had 3 earnings beat's and 1 earnings miss's. The average earnings beat has been 12.1% and the average earnings miss has been 8.2%.
When is Abbott Laboratories's next earnings date and what are the expectations?
Abbott Laboratories is set to report earnings on 30 July 2019 after market close. The report will be for the fiscal Quarter ending June 2019. Based on 14 analysts' forecasts, the consensus EPS forecast for the quarter is $2.12. Recent analyst revisions have been positive implying a potential EPS of $2.24.
What is Abbott Laboratories's upcoming earnings report expectations?
The earnings expectations for Abbott Laboratories's upcoming report on 30 July 2019 are from 14 analysts with an average EPS of $2.12. The lowest analyst rating is $2.01, the highest is $2.84. The most recent earnings revisions have been positive with a most recent estimate of $2.24.
What is Abbott Laboratories's earnings per share (EPS)?
Abbott Laboratories's latest earnings per share (EPS) was reported as $2.02 on 30 April 2019 for fiscal quarter ending March 2019. This is 11.0% higher than 12 months ago when they reported EPS of $1.82
What is Abbott Laboratories's dividend growth rate?
Abbott Laboratories's dividends have grown at 14.29% in the past year and an average growth of 8.33% over the past 4 years. This is higher then it's competitors 4-year average dividend growth of 4.1
What is Abbott Laboratories's dividend yield?
Abbott Laboratories's current dividend yield is 0.38%. This is calculated by taking the dividend's per share of $0.32 (the last payment which was on 12 July 2019) and dividing by the current share price of $84.78.
What is Abbott Laboratories's previous and next dividend date?
Abbott Laboratories's most recent dividend date was 12 July 2019 when the company paid $0.32 and the next dividend date is 11 October 2019 with an expected payment of $0.32.